Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (12379)	12/3/1999 10:19:00 AM
From: Cacaito	Read Replies (2) \| Respond to of 17367

xoma/DNA hull24 also get rid of T cells (if they ever start the thing, otherwise yes they will not get rid of T cells). Pharmas made tons of mistakes, look at all the money Pfizer put on E5, Schering in zona's garbage, and J&J in Ergo garbage, Pfizer in super failure Neurogen. And big pharma also err when leaving value to others like Ligands got back rights on Targretin, ALLP got rights back from J&J on oxygent, and these are the ones that comes quick to my mind. And Takeda is not puting the whole $73 M ahead, only $13M and the rest depends on milestones. The $13M is a drop on next year tax expenses claims.